Develop and commercialize medicines for cardiovascular diseases. Focus on oncology therapeutics for various types of cancers. Now — the numbers.
There is not enough trading history here to call this an established business.
Red columns mark years that ended in a loss.
If every debt were paid off today, $9.4M would still be left in the vault — a solid cushion for hard times.
The market pays 0.9× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $9.4M in the vault; even if every debt were paid off, $9.4M would remain.
The stock sits at $0.04. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.